Zubsolv® is a schedule III buprenorphine/naloxone combination medication specifically indicated (and FDA approved) for the treatment of opioid addiction. Along with Suboxone®, its generic equivalents, Subutex® (discontinued in the US), its generic equivalents, Zubsolv is a medication subject to DATA-2000.
FDA approved on July 3, 2013 and commercially launched in September 2013, Zubsolv is the first brand name competitor to Suboxone. Manufacturer copay card available - up to $225 off
Zubsolv has a higher bioavailability than Suboxone and as a result comes in different doses than Subxone or generics. Zubsolv comes in sublingual tablet sizes of 5.7-mg/1.4-mg (buprenorphine/naloxone), and 1.4-mg/0.36-mg (buprenorphine/naloxone) both have equal bioavailability to 8mg/2mg and 4mg/1mg of competing buprenorphine/naloxone products, respectively. Sub-to-Zub dose conversion tool
UPDATE: On March 6, 2015 Orexo US, Inc. announced the FDA approval of the new 8.6mg/2.1mg dosage strength of ZUBSOLV®. This corresponds to 12mg/3mg of generic bup/nx dosing.
Zubsolv is individually packaged to reduce accidental pediatric exposure.
See the Zubsolv website for more info: zubsolv.com
To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -